Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 9/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 7/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864862 | 0.87 | SMN1; SMN2 (0.54) | SCN8ASIGMAR1SCN1AROCK1ROCK2 | |
| SCHEMBL5865032 | 0.83 | SCN8A (0.59) | SCN8AACHESCN9ASIGMAR1SCN1A | |
| SCHEMBL5864926 | 0.81 | TRPV6 (0.42) | SCN8ACHRNB2CHRNA4TRPV6 | |
| SCHEMBL8395893 | 0.78 | TRPV6 (0.61) | SCN9ASIGMAR1CHRNB2CHRNA4ROCK1 | |
| SCHEMBL5864786 | 0.77 | SCN1A (0.55) | SCN8AACHESIGMAR1SCN1ADRD2 | |
| SCHEMBL12193268 | 0.77 | ROCK1 (0.54) | SCN8ASCN9ACHRNB2CHRNA4ROCK1 | |
| SCHEMBL5864782 | 0.76 | HRH3 (0.48) | SCN8AHTR4SCN1A | |
| SCHEMBL19634251 | 0.76 | SCN8A (0.69) | SCN8ASCN1A | |
| SCHEMBL27618840 | 0.76 | CHRNB2 (0.62) | SCN9ASIGMAR1CHRNB2CHRNA4DRD2 | |
| SCHEMBL19612881 | 0.75 | SCN8A (1.00) | SCN8ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | SCN8A 763/4885ACHE 1254/4885SCN9A 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.